Filing Details
- Accession Number:
- 0001166280-14-000001
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-01-17 19:18:42
- Reporting Period:
- 2014-01-17
- Filing Date:
- 2014-01-17
- Accepted Time:
- 2014-01-17 19:18:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1080709 | Arena Pharmaceuticals Inc | ARNA | Pharmaceutical Preparations (2834) | 232908305 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1166280 | Jack Lief | C/O Arena Pharmaceuticals, Inc. 6154 Nancy Ridge Drive San Diego CA 92121 | Chairman, President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-01-17 | 100,000 | $6.00 | 683,704 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-01-17 | 100,000 | $7.81 | 583,704 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2014-01-17 | 100,000 | $0.00 | 100,000 | $6.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2004-01-18 | 2014-01-18 | No | 4 | M | Direct |
Footnotes
- The amount includes shares purchased under Arena's employee stock purchase plan prior to the reported transaction.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $7.67 and $7.92 per share, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The options were exercisable upon grant, but vested in four approximately equal annual installments beginning on January 18, 2005.
Billionaire Hedge Funds
